Celgene Corporation (Nasdaq:CELG) hit a new 52-week high Monday as it is currently trading at $96.35, above its previous 52-week high of $96.33 with 2.2 million shares traded as of 1:11 p.m. ET. Average volume has been 3.2 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Celgene Corporation (Nasdaq: CELG) hit a new 52-week high Monday as it is currently trading at $96.35, above its previous 52-week high of $96.33 with 2.2 million shares traded as of 1:11 p.m. ET. Average volume has been 3.2 million shares over the past 30 days. Celgene has a market cap of $40.39 billion and is part of the health care sector and drugs industry. Shares are up 21.7% year to date as of the close of trading on Friday. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. The company has a P/E ratio of 26.5, above the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Celgene Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.